551:
defendants “orchestrated a smear campaign against
Cassava that included more than 1,000 false and defamatory statements.” On March 28, 2024, the judge dismissed Cassava's lawsuit, finding "that the majority of the defendants' statements were protected under the First Amendment as statements of opinion or scientific debate, and that the fraction of statements that were adequately alleged to be defamatory were not published with actual malice". The short-sellers had claimed that Hoau-Yan Wang's research on its experimental Alzheimer's drug was fabricated. Cassava refiled its suit against the four short-sellers in April 2024, but dropped the lawsuit in August after Wang was charged with submitting false data to the NIH.
657:. He writes that the paper relied on a method of analyzing how brain tissue "purportedly generates chemical signals"; Schrag found no indication the work, which he says "contradicts basic neurobiology", had been replicated. He sent two groups of images to JCI; the editor responded that they did not investigate further after examination of one of the groups did not corroborate Schrag's analysis. A group of four whistle-blowers also submitted concerns about the paper starting in August 2021. The four whistleblowers were independent of the two that filed the FDA petition, but they were also holding short positions on Cassava. JCI's investigation did not corroborate their concerns about the paper.
508:. When the petition was filed, Bredt was an executive partner at a firm that raised investment capital for another biotechnology company working on Alzheimer's treatment. He had noticed Cassava Sciences when its stock price increased in 2021 following early positive trial results for simufilam. After examining the preclinical research papers, Bredt remarked that "they were making statements that were incompatible with biology and with pharmacology", and said that if the research was in fact legitimate, it should "win five Nobel Prizes". According to
512:, Cassava's initial report that the reanalysis of simufilam's effectiveness was done by "an outside lab"—later revealed to be the CUNY lab of Wang, "a longtime paid consultant to the company"—was not revealed to investors; the news had led to a doubling of the company's stock price. Bredt and Pitt suspected the re-analysis had been done by Wang, which was later confirmed by Barbier. Barbier responded that Wang was not an employee, so he considered his lab separate. Among other methodological concerns, the petitioners suspected irregularities in
634:, two of which were co-authored with Burns that include the original papers on the discovery of FLNA binding as it relates to opioid receptor signaling. The FLNA retraction notices mention "vertical irregularities suggestive of splice lines" and that the "pixel patterns in background areas of blot images ... appear more similar than would be expected". The notices state: "The data and comments provided did not resolve the concerns about the integrity and reliability of data presented in this article."
465:
clinical trials of simufilam." Kate Moss, attorney, stated via email to
Reuters in July 2022 that "Cassava Sciences ... has never been charged with a crime, and for good reason – Cassava Sciences has never engaged in criminal conduct." Piller summarized an email from Barbier as saying Cassava had "hired investigators to review its work, provided 'nearly 100,000 pages of documents to an alphabet soup of outside investigative agencies,' and asked CUNY to investigate ... "
2323:"Requests that the FDA halt the current clinical studies of Simufilam PTI-125 sponsored by Cassava Sciences NCT04388254 and NCT04994483, pending audits of 1 the publications relied on by Cassava in support of its scientific claims concerning Simufilam; 2 the IND application for Simulifam's use in Alzheimer's Disease; and 3 all clinical biomarker studies of Simufilam in Alzheimer's Disease"
497:, Thomas certified that the petition included "information known to the petitioner which are unfavorable to the petition". Cassava Sciences maintained that the claims about the research data were "outlandish" and said the FDA's process had been used abusively. Cassava's stock value dropped 55% after the petition was filed.
615:
found "no compelling evidence of data manipulation intended to misrepresent the results", but issued an expression of concern on a 2017 paper, saying they identified multiple errors. The journal issued a correction and indicated that its final decision awaited conclusions from the CUNY investigation.
521:
shares of
Cassava Sciences, expecting the price of its stock to drop once problems with the research were revealed. After the stock's precipitous drop caused by the FDA petition, it was revealed that they were short sellers; Compliance Week stated that Thomas had not revealed this information when he
460:
stated in 2021 that the SEC, the NIH, and CUNY were investigating allegations of manipulated data. In
October 2023, CUNY reported that they could obtain none of Wang's original data, which meant that they were unable to either prove or disprove allegations that the images were improperly manipulated;
601:
reassessed the 2012 paper that described simufilam binding to FLNA. The journal published a correction along with the original images in
December 2021 remarking that the "error does not affect the conclusions of the article". After further data concerns were brought to the attention of the journal,
464:
Cassava
Sciences has denied any wrongdoing. Following Wang's June 2024 indictment, Cassava Sciences issued a press release stating that, "Wang's work under these grants was related to the early development phases of the Company's drug candidate ... had no involvement in the Company’s Phase 3
253:
in
January 2022 that Cassava's bonus plan provides for potential cash bonuses tied to "specific valuations for twenty consecutive days". He added that the "full incentive scheme could exceed two hundred million dollars, and it was not pegged to F.D.A. approval or to the success of the drug—just to
408:
of PTI-125 had failed, but reported in
September 2020 that a new analysis by an "outside lab" showed improvements in biomarkers, adding that individuals with Alzheimer's also showed improvements in cognition with simufilam. It was later revealed that the outside lab was Wang's CUNY lab. In October
295:
The WSJ wrote that, due to the promise of its experimental
Alzheimer's drug, Cassava Sciences stock became the sixth-best stock of 2021, driving the company's value to over $ US5 billion, with the stock price reaching $ 125 per share. Keefe noted that part of the increase in share price was
230:
Remi
Barbier was Cassava's president, chief executive officer and chairman of the board until his abrupt July 2024 resignation, when Richard J. (Rick) Barry was named executive chairman of the board. A new permanent CEO search was initiated, with the outgoing CEO, Barbier, to remain employed by
550:
On November 3, 2022, Cassava Sciences filed a defamation lawsuit in the U.S. District Court of the Southern District of New York against defendants Quintessential Capital Management LLC, Drs. David Bredt and Geoffrey Pitt and other short sellers. According to Bloomberg, the lawsuit alleges that
234:
Other officers, as of July 2024, are James W. Kupiec, chief medical officer, and Eric Schoen, chief financial officer. Senior vice presidents are: R. Christopher Cook (senior counsel), Michael Marsman (regulatory affairs), Michael Zamloot (tech operations), and George Thornton (technology).
399:
was assigned to the company's experimental drug, previously called PTI-125, which Cassava Sciences says can restore misshaped FLNA in the brain. Open-label studies had started in March 2020, and Cassava Sciences had reported in May 2020 that initial biomarker analysis of
2203:
Subbaraman N, Walker J (October 13, 2023). "Cassava Sciences Adviser Found to Have Committed 'Egregious Misconduct'; Scientist, who is a City University of New York professor, didn't provide school investigators with data or records supporting his research".
643:
journal article on opioid tolerance was co-authored by Burns, Wang and others. According to Piller, Cassava has stated that the journal found no manipulation of images, but said the journal would respond to any new concerns based on the CUNY investigation.
380:
Remoxy was a twice-daily gel form of oxycodone intended to be abuse-deterrent. It was repeatedly rejected by the FDA, culminating in the final rejection in 2018 after an FDA advisory meeting raised concerns about its potential risk of abuse. According to
217:(FDA) rejection of one of its experimental pain drugs, Remoxy, Cassava announced in August 2018 it would reorganize the company to focus on products for treating and diagnosing Alzheimer's. In 2019, the company changed its name to Cassava Sciences.
409:
2021, larger trials were initiated; Cassava Sciences announced in December 2021 that the first phase III trial of simufilam would enroll about 750 participants, and the second 1,000. In the first quarter of 2022, 60 participants were enrolled;
563:
article stated in April 2022 that "many scientists have been deeply skeptical of the company's claims, asserting that Cassava's studies were flawed, its methods opaque and its results improbable". Robert Howard, professor of psychiatry at the
516:
images in papers by Wang and Burns, and were concerned that the 2020 "reanalysis" of findings by Wang had not been disclosed in Cassava's filings and that individuals enrolled in trials would be taking a drug that might not be safe. They
277:(WSJ) stated in 2021 that, along with Cassava's officers, he could receive bonuses based on Cassava's market performance; he was indicted in June 2024 for falsifying data related to Cassava's Alzheimer's drug in development, simufilam.
546:
The FDA rejected the petition in February 2022 because the requests were "not the appropriate subject of a citizen petition", saying also that the rejection was not “a decision by the agency to take or refrain from taking any action”.
180:. The company had no drug approved as of 2021, and no product revenues between 2013 and 2021; with 25 employees, the company's stock was the sixth-best performing in 2021 before falling after concerns over simufilam research.
2359:
1941:
300:. The share price fell to $ 42 after a petition was filed with the FDA in August 2021, questioning the company's research. After Wang's June 2024 indictment, the stock fell by 46% to a new low of about $ 10 per share.
454:(FDA), but the FDA said that the citizen petition "was not a proper avenue" to stop the trials in February 2022. The request that FDA conduct an investigation fell out of the purview of the citizen petition process.
537:
as another whistleblower who examined images. Schrag reported to the NIH irregularities in 34 papers with authors linked to Cassava Sciences or its work, including Wang, Burns and Cassava advisor Steven Arnold, a
542:
neurologist. Schrag was paid $ 18,000 by the petitioners' attorney for his hundreds of hours of analysis of the images. Piller contacted other experts who he said "generally agree" with Schrag's conclusions.
3013:
Wang HY, Friedman E, Olmstead MC, Burns LH (2005). "Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling".
584:, also commented: "The overall conclusions with regard to Alzheimer's disease make no sense to me whatsoever... are not in the mainstream of the field, and to me they seem implausible and contrived."
3086:
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (April 2012).
1328:
622:
investigated a 2020 simufilam-related, also co-authored by Wang, and decided to take no action. Its editor reported finding "no convincing evidence of manipulation of data or intent to mislead".
572:, image-manipulation consultant, agreed to the citizen petition and alleged data errors and inconsistencies in the publications, identifying potential irregularities consistent with instances of
385:, the FDA reprimanded Cassava Sciences for appearing to promote the unapproved drug. Barbier accused the FDA of "math errors, material mistakes and misrepresentations", which the agency denied.
2155:
332:
buildup in the brain contributing to the disease; Cassava journal papers, co-authored by Wang and Burns, suggest that the shape of FLNA in the brain can be restored. A 2022 article in
2367:
440:
journal's Piller called the report "damning", saying the FDA found a "litany of problems" that raise "questions about the credibility of claims by Wang and Cassava about simufilam".
201:
in New York City around 1993. Crain invited Barbier to his lab and explained the potential pharmaceutical and financial benefits. In 1998, Barbier started Pain Therapeutics, Inc. in
2814:"Expression of Concern: Wang et al., (2017) PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiol. Aging, 55:99–114"
2566:
254:
the share price. This appeared to create an incentive for the company to pump its own stock." The WSJ stated that, under this plan, Barbier's bonus could reach $ 108 million.
526:
reported that the August selloff of Cassava shares earned short sellers $ 100 million, and Compliance Week stated that Bredt and Pitt "potentially ... made millions".
485:—alleging concerns about unreliable research and potential data manipulation in Cassava Science's preclinical research for the experimental drug. The petition was submitted by
2755:
Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH (July 2017). "PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis".
2521:
1893:
1919:
1119:
1250:
1141:
1224:
3193:
2102:
1990:
1473:
3188:
3070:
2591:
338:
stated that none of the Alzheimer's experts they spoke with knew of any support for the FLNA hypothesis; Lawrence Sterling Honig, professor of neurology at
241:
the senior vice president for neuroscience and Barbier's wife also resigned in 2024 following the indictment of her co-researcher Wang on charges of fraud.
1454:
606:
stating that the issue was under investigation by CUNY, and that the journal would "await the outcome of that investigation before taking further action".
2036:
1374:
3088:"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline"
2181:
678:
1584:
2854:
534:
2058:
342:, said: "But in fact, all the evidence seems to be from this lab." (Wang and Burns had earlier published together on FLNA's role in naloxone and
3168:
2472:
3183:
2013:
3178:
482:
2881:"Retraction: High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence"
1703:"Retraction: High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence"
2948:"Retraction: Naloxone's Pentapeptide Binding Site on Filamin A Blocks Mu Opioid Receptor–Gs Coupling and CREB Activation of Acute Morphine"
1641:"Retraction: Naloxone's Pentapeptide Binding Site on Filamin A Blocks Mu Opioid Receptor–Gs Coupling and CREB Activation of Acute Morphine"
1610:
630:
re-examined Wang's research papers in March 2020 and found problems with data integrity that were not resolved. Five of Wang's papers were
2700:"Expression of Concern: Wang et al., "Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A""
2617:
425:(DOJ) for fraud and charged with falsifying data on $ 16 million in grant applications to the NIH related to simufilam. The DOJ and the
3158:
1432:
937:
433:
3173:
1277:
339:
176:
Cassava (as Pain Therapeutics) initially worked on three drugs: the pain drugs Oxytrex and Remoxy, and PTI-901, which aimed to treat
3163:
1967:
1846:
1558:
3143:
1871:
2540:
426:
413:
stated that enrollment had slowed as of April 2022, as people were deterred from enlisting due to the prevailing controversies.
373:, a generic opioid, combined with ultra-low-dose naltrexone that aimed to enhance analgesia while reducing opioid tolerance and
169:. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with
1532:
2644:"Erratum: Wang et al., "Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A""
2279:
1920:"Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer's Disease"
795:
422:
198:
162:
1163:
493:
in New York City, and requested that the FDA halt the clinical trials until the issues could be resolved. According to
1213:
568:, remarked that the lack of placebo and small sample size meant research conclusions were "implausible" at the least.
649:
631:
2228:
1410:
1388:
267:, Barbier would not specify in 2022 who were the company's 2022 scientific advisers. Hoau-Yan Wang, a professor at
461:
they paused the investigation a few weeks later over concerns about confidentiality and integrity of the process.
271:(CUNY) is a consultant who was on Cassava's advisory board. He is a co-author, with Burns, of many journal papers.
1760:
Burns LH, Wang HY (November 2010). "PTI-609: a novel analgesic that binds filamin A to control opioid signaling".
405:
1120:"Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives"
1091:"With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer's disease world"
202:
88:
2445:
1942:"Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer's Disease"
1090:
1503:
1024:
933:
500:
The petitioners who filed the FDA complaint were identified months later, in November 2021, as neuroscientist
429:(SEC) were also investigating two senior Cassava employees. Barbier and Burns abruptly resigned in July 2024.
505:
289:
724:
592:
Several journal papers involving Cassava work and collaborators have been re-examined by their publishers.
474:
451:
214:
653:(JCI); Piller states that it forms a key part of Cassava's position that simufilam reduces resistance to
597:
268:
155:
143:. The company was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.
959:
446:
reported in July 2022 that a criminal investigation of Cassava Sciences had been started by the DOJ. A
1533:"Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer's drug"
565:
673:
The company's SEC Form 10-K filings from 2021 state that Scientific Advisory Board members included
2254:
363:
328:) is a protein that Cassava Sciences says becomes misshaped in people with Alzheimer's, leading to
177:
699:
231:
Cassava until September 13, 2024 in a non-executive capacity, without duties or responsibilities.
1991:"Scientist behind Alzheimer's drug in late-stage trials is indicted on charges of research fraud"
273:
2103:"'Damning' FDA inspection report undermines positive trial results of possible Alzheimer's drug"
150:(previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of
828:
639:
151:
136:
2394:
Else H (January 2023). "Alzheimer's drug saga prompts journal to scrutinize whistle-blowers".
2322:
1251:"Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer's drug studies"
3050:
2791:
2360:"The Cassava Sciences saga: Short sellers, 'gaming' the FDA, and the damaging ripple effects"
2209:
2156:"Exclusive: Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say"
854:
611:
603:
530:
2498:
1212:
193:
Cassava Sciences was founded by Remi Barbier in May 1998 as Pain Therapeutics, focusing on
2959:
2892:
2403:
1801:
1714:
1652:
1342:
1208:
478:
447:
374:
244:
1285:
8:
2830:
2813:
2799:
2768:
581:
401:
359:
2963:
2896:
2407:
1718:
1656:
1346:
1142:"Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD"
577:
3112:
3087:
3058:
3039:
3027:
2990:
2947:
2923:
2880:
2835:
2780:
2732:
2676:
2643:
2427:
1828:
1737:
1702:
1675:
1640:
1366:
539:
334:
3117:
3062:
3031:
2995:
2977:
2928:
2910:
2839:
2784:
2772:
2737:
2719:
2681:
2663:
2431:
2419:
2287:
2182:
Co-developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct'
2124:
2107:
2069:
1820:
1777:
1742:
1680:
1448:
1370:
1358:
1333:
1032:
909:
803:
647:
Cassava advisors Wang and Arnold were co-authors on a highly-cited 2012 paper in the
263:
197:
and chronic pain. Barbier first heard of the research led by Stanley M. Crain at the
56:
3043:
2592:"Two expressions of concern arrive for papers linked to beleaguered biotech Cassava"
1832:
3107:
3099:
3054:
3023:
2985:
2967:
2918:
2900:
2825:
2795:
2764:
2727:
2715:
2711:
2671:
2659:
2655:
2621:
2595:
2567:"Biotech firm drops defamation suit against short-sellers after researcher charged"
2411:
2292:
2185:
2116:
2073:
1810:
1769:
1732:
1722:
1670:
1660:
1614:
1411:"United States Securities and Exchange Commission Form 10-K, Cassava Sciences, Inc"
1389:"United States Securities and Exchange Commission Form 10-K, Cassava Sciences, Inc"
1350:
904:
899:
887:
682:
674:
490:
486:
2972:
2905:
2363:
2213:
1727:
1665:
494:
343:
66:
1872:"A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy"
796:"SEC Investigating Cassava Sciences, Developer of Experimental Alzheimer's Drug"
2476:
2415:
2177:
2098:
1773:
1324:
1255:
1219:
686:
573:
523:
501:
410:
258:
249:
158:
38:
1435:. Cassava Sciences. March 5, 2021. Archived from the original on March 5, 2021
3152:
2981:
2914:
2723:
2699:
2667:
1167:
1062:
1036:
807:
569:
238:
170:
140:
107:
46:
2296:
2189:
2120:
2077:
1354:
3121:
3066:
3035:
2999:
2932:
2776:
2741:
2685:
2423:
2128:
1824:
1781:
1746:
1684:
1362:
913:
513:
173:, his wife, who was a Cassava senior vice president and Wang's co-author.
2037:"Cassava Sciences forms internal panel after US probe into two employees"
2014:"US professor charged with manipulating data for Alzheimer's drug trial"
1968:"Professor Charged for Operating Multimillion-Dollar Grant Fraud Scheme"
1815:
1796:
960:"FDA declines to approve Pain Therapeutics' opioid drug, shares plunge"
518:
297:
296:
driven by discussion and hype in online forums, making it a so-called
3103:
395:
370:
147:
2229:"Scientists Investigating Alzheimer's Drug Faulted in Leaked Report"
702:
for NIH grants totaling over $ 20 million for Cassava Sciences.
3138:
626:
1894:"USAN Modifies Lead Drug Candidate's Chemical Name to 'simufilam'"
1025:"Scientists Question Data Behind an Experimental Alzheimer's Drug"
119:
2855:"PLOS ONE Pulls Five Papers Tied to Alzheimer's Drug Controversy"
2522:"Meme Stock Cassava Sues Short Sellers Alleging a Smear Campaign"
963:
654:
443:
329:
2618:"Journal mulls expression of concern for Cassava Sciences paper"
1634:
1632:
292:(NIH) grants totalling $ 20 million between 2015 and 2021.
2473:"Cassava Short Sellers Reap $ 100 Million in August Stock Rout"
725:"Executives Depart Cassava, Maker of Disputed Alzheimer's Drug"
355:
194:
52:
2280:"Science podcast 220722 with Charles Piller and Sarah Crespi"
1629:
1585:"Cassava Sciences' Shares Down 46% After Adviser Is Indicted"
1474:"Cassava Sciences Issues Statement on Former Science Advisor"
450:
attempting to suspend the clinical trials was filed with the
888:"Janus-Faced Drugs: The Double-Edged Synthetic Opiate Trade"
167:
fraud over research results related to the experimental drug
165:
charged an advisor to Cassava Sciences, Hoau-Yan Wang, with
2541:"Drug Company's Libel Lawsuit Against Scientists Dismissed"
1847:"Pain Therapeutics slumps as Oxytrex fails Phase III trial"
377:. The phase III trials had high drop out rates and failed.
325:
285:
The company had no product revenues between 2013 and 2021.
1696:
1694:
354:
The company started with three drug candidates focused on
3012:
1948:(Press release). Cassava Sciences, Inc. December 23, 2021
1900:(Press release). Cassava Sciences, Inc. November 27, 2020
2945:
2878:
1970:(Press release). US Department of Justice. June 28, 2024
1504:"Embattled Alzheimer's Researcher Is Charged With Fraud"
1691:
2149:
2147:
2145:
1922:(Press release). Cassava Sciences. September 14, 2020
2255:"CUNY Halts Investigation of Alzheimer's Researcher"
1559:"Cassava Sciences Adviser Indicted on Fraud Charges"
794:
Michaels, Dave; Walker, Joseph (November 17, 2021).
2499:"Response Letter from FDA CDER to Labaton Sucharow"
2142:
1611:"Five studies linked to Cassava Sciences retracted"
432:A September 2022 FDA report was obtained under the
205:, with an initial investment of $ 1 million.
2353:
2351:
2349:
2347:
2345:
2226:
829:"Pain Therapeutics, Inc. – Cruelty Free Investing"
166:
3085:
1244:
1242:
1018:
1016:
1014:
1012:
1010:
1008:
1006:
1004:
1002:
1000:
504:, and cardiologist Geoffrey Pitt, a professor at
3150:
2202:
2035:Santhosh, Christy; Jain, Pratik (July 1, 2024).
1700:
1638:
1476:(Press release). Cassava Sciences. June 28, 2024
1453:: CS1 maint: bot: original URL status unknown (
1122:(Press release). Cassava Sciences. July 17, 2024
998:
996:
994:
992:
990:
988:
986:
984:
982:
980:
620:The Journal of Prevention of Alzheimer’s Disease
416:
3144:CUNY investigation report on simufilam research
2342:
2154:Taylor, Marisa; Spector, Mike (July 27, 2022).
1114:
1112:
1110:
1108:
958:Mishra, Manas; Shyam, Ashwin (August 6, 2018).
716:
308:As of November 2021, Cassava had 25 employees.
2754:
2519:
2272:
1239:
927:
925:
923:
793:
468:
349:
3194:Pharmaceutical companies of the United States
2389:
2387:
2385:
2153:
1319:
1317:
1315:
1313:
1311:
1309:
1307:
1305:
1303:
977:
881:
879:
877:
875:
855:"SAVA – Cassava Sciences Inc Company Profile"
316:The company had no drug approved as of 2021.
3189:Pharmaceutical companies established in 1998
2464:
2034:
2012:Cohen, Luc; Taylor, Marisa (June 28, 2024).
1526:
1524:
1203:
1201:
1199:
1197:
1195:
1193:
1191:
1189:
1187:
1185:
1105:
1057:
1055:
1053:
2946:PLOS ONE Editorial Board (March 30, 2022).
2879:PLOS ONE Editorial Board (March 30, 2022).
2748:
2170:
2011:
1866:
1864:
1552:
1550:
1497:
1495:
1493:
1491:
957:
920:
789:
787:
785:
783:
781:
779:
777:
775:
773:
771:
769:
767:
765:
288:Cassava and its collaborators were awarded
2806:
2382:
2252:
2091:
1788:
1501:
1413:. Cassava Sciences, Inc. February 28, 2022
1300:
1248:
1088:
1084:
1082:
1080:
1022:
938:Genetic Engineering and Biotechnology News
872:
763:
761:
759:
757:
755:
753:
751:
749:
747:
745:
722:
3111:
2989:
2971:
2922:
2904:
2829:
2731:
2675:
2610:
2584:
2496:
1814:
1759:
1736:
1726:
1674:
1664:
1582:
1521:
1214:"Jordan Thomas's Army of Whistle-Blowers"
1182:
1134:
1050:
903:
587:
340:Columbia University Irving Medical Center
2520:Benny-Morrison, Ava (November 3, 2022).
2470:
2253:Mandavilli, Apoorva (October 28, 2023).
2196:
1861:
1547:
1488:
934:"Pain Therapeutics Takes Different Path"
931:
554:
358:treatment: Oxytrex, Remoxy and PTI-901 (
2227:Apoorva Mandavilli (October 14, 2023).
2051:
1468:
1466:
1464:
1391:. Cassava Sciences, Inc. March 23, 2021
1270:
1077:
932:Sturgeon, Christopher (June 15, 2006).
885:
742:
427:U.S. Securities and Exchange Commission
421:In June 2024, Wang was indicted by the
3169:American companies established in 1998
3151:
2538:
2357:
2336:
2309:
2176:
2097:
1794:
1556:
1323:
1023:Mandavilli, Apoorva (April 18, 2022).
388:
311:
3184:Medical scandals in the United States
2564:
2471:Flanagan, Cristin (August 31, 2021).
1960:
1530:
1502:Mandavilli, Apoorva (June 28, 2024).
1207:
951:
3179:Health care companies based in Texas
2852:
2831:10.1016/j.neurobiolaging.2022.03.012
2800:10.1016/j.neurobiolaging.2022.03.012
2769:10.1016/j.neurobiolaging.2017.03.016
2393:
1988:
1461:
595:Following the public controversies,
220:
1701:PLOS ONE Editors (March 30, 2022).
1639:PLOS ONE Editors (March 30, 2022).
723:Rosenbluth, Teddy (July 18, 2024).
580:, Nobel laureate neuroscientist at
423:United States Department of Justice
199:Albert Einstein College of Medicine
163:United States Department of Justice
13:
3059:10.1016/j.neuroscience.2021.11.019
3028:10.1016/j.neuroscience.2005.06.003
2497:Cavazzoni, P. (February 9, 2022).
1249:Feuerstein, Adam (April 5, 2022).
1227:from the original on July 22, 2022
1166:. Cassava Sciences. Archived from
1089:Feuerstein, Adam (July 17, 2024).
393:In August 2020, the chemical name
319:
14:
3205:
3159:1998 establishments in California
3132:
2539:Volokh, Eugene (March 29, 2024).
2059:"Establishment Inspection Report"
1583:Beckerman, Josh (June 28, 2024).
1531:Wosen, Jonathan (June 28, 2024).
650:Journal of Clinical Investigation
489:, who was then with the law firm
3174:Companies based in Austin, Texas
2654:(50): 10405. December 15, 2021.
2358:Jaeger, Jaclyn (March 2, 2022).
1849:. PharmaTimes. November 23, 2005
1557:Walker, Joseph (June 28, 2024).
700:Reporter.nih.gov Advanced search
529:In July 2022, Piller identified
522:certified the citizen petition.
3079:
3006:
2939:
2872:
2846:
2692:
2636:
2558:
2532:
2513:
2490:
2438:
2315:
2246:
2220:
2028:
2005:
1982:
1934:
1912:
1886:
1839:
1753:
1603:
1576:
1425:
1403:
1381:
1156:
692:
667:
203:South San Francisco, California
89:South San Francisco, California
16:American pharmaceutical company
2716:10.1523/JNEUROSCI.2306-21.2021
2660:10.1523/JNEUROSCI.2154-21.2021
905:10.1016/j.chembiol.2005.10.003
847:
821:
576:across different experiments.
208:
161:as of 2022. In June 2024, the
1:
3049:(This paper currently has an
2790:(This paper currently has an
2565:Cohen, Luc (August 5, 2024).
2446:"Corrections: April 20, 2022"
1144:. BioSpace. December 20, 2022
709:
506:Weill Cornell Medical College
434:US Freedom of Information Act
417:Allegations of research fraud
290:National Institutes of Health
225:
3164:Alzheimer's disease research
2973:10.1371/journal.pone.0266629
2906:10.1371/journal.pone.0266627
2853:Akst, Jef (March 31, 2022).
2710:(3): 529. January 19, 2022.
1989:Bush, Evan (June 28, 2024).
1728:10.1371/journal.pone.0266627
1666:10.1371/journal.pone.0266629
475:Food and Drug Administration
452:Food and Drug Administration
280:
215:Food and Drug Administration
7:
2648:The Journal of Neuroscience
1433:"Scientific Advisory Board"
1278:"Lindsay Burns Barbier '87"
598:The Journal of Neuroscience
469:Citizen petition to the FDA
350:Oxytrex, Remoxy and PTI-901
303:
269:City University of New York
188:
78:; 26 years ago
10:
3210:
2416:10.1038/d41586-023-00050-z
1774:10.2174/157488910793362386
1762:Recent Pat CNS Drug Discov
1282:www.harvardvarsityclub.org
183:
566:University College London
406:phase IIb clinical trials
369:Oxytrex was a mixture of
114:
103:
95:
72:
62:
44:
34:
26:
833:crueltyfreeinvesting.org
660:
481:–filed on behalf of two
364:irritable bowel syndrome
178:irritable bowel syndrome
2704:Journal of Neuroscience
2297:10.1126/science.ade0384
2190:10.1126/science.adl3444
2121:10.1126/science.adp1964
2078:10.1126/science.z7wo4zp
1946:GlobeNewswire News Room
1898:GlobeNewswire News Room
1563:The Wall Street Journal
1355:10.1126/science.add9993
892:Chemistry & Biology
886:Wolfson, Wendy (2005).
510:The Wall Street Journal
458:The Wall Street Journal
404:(CSF) samples from its
274:The Wall Street Journal
30:Pain Therapeutics, Inc.
588:Journal investigations
146:Cassava is developing
137:pharmaceutical company
22:Cassava Sciences, Inc.
3051:expression of concern
2818:Neurobiology of Aging
2792:expression of concern
1209:Keefe, Patrick Radden
612:Neurobiology of Aging
604:expression of concern
555:Other concerns raised
531:Vanderbilt University
213:Following the fourth
2180:(October 12, 2023).
1802:Nature Biotechnology
1795:Jacobs, Tom (2005).
1211:(January 15, 2022).
689:, and Hoau-Yan Wang.
473:In August 2021, the
2964:2022PLoSO..1766629.
2897:2022PLoSO..1766627.
2624:. November 22, 2021
2598:. December 20, 2021
2408:2023Natur.613..618E
2206:Wall Street Journal
2184:(Report). Science.
2115:(6688): 1165–1166.
1816:10.1038/nbt0805-934
1797:"No pain, no gain?"
1719:2022PLoSO..1766627.
1657:2022PLoSO..1766629.
1377:on August 28, 2022.
1347:2022Sci...377..358P
1329:"Blots on a field?"
800:Wall Street Journal
582:Stanford University
402:cerebrospinal fluid
389:Alzheimer's disease
375:withdrawal symptoms
360:low-dose naltrexone
312:Research candidates
152:Alzheimer's disease
23:
2450:The New York Times
2259:The New York Times
2101:(March 11, 2024).
1508:The New York Times
1065:. Cassava Sciences
1029:The New York Times
540:Harvard University
383:The New York Times
335:The New York Times
154:; simufilam is in
21:
2501:. regulations.gov
2402:(7945): 618–619.
2370:on August 1, 2022
2335:As referenced by
2325:. regulations.gov
2291:. July 22, 2022.
1341:(6604): 358–363.
1327:(July 21, 2022).
898:(10): 1055–1056.
477:(FDA) received a
436:; in March 2024,
221:Corporate affairs
130:
129:
3201:
3126:
3125:
3115:
3104:10.1172/JCI59903
3083:
3077:
3076:
3072:Retraction Watch
3047:
3010:
3004:
3003:
2993:
2975:
2943:
2937:
2936:
2926:
2908:
2876:
2870:
2869:
2867:
2865:
2850:
2844:
2843:
2833:
2810:
2804:
2803:
2788:
2752:
2746:
2745:
2735:
2696:
2690:
2689:
2679:
2640:
2634:
2633:
2631:
2629:
2622:Retraction Watch
2614:
2608:
2607:
2605:
2603:
2596:Retraction Watch
2588:
2582:
2581:
2579:
2577:
2562:
2556:
2555:
2553:
2551:
2536:
2530:
2529:
2517:
2511:
2510:
2508:
2506:
2494:
2488:
2487:
2485:
2483:
2468:
2462:
2461:
2459:
2457:
2452:. April 19, 2022
2442:
2436:
2435:
2391:
2380:
2379:
2377:
2375:
2366:. Archived from
2355:
2340:
2334:
2332:
2330:
2319:
2313:
2307:
2305:
2303:
2284:
2276:
2270:
2269:
2267:
2265:
2250:
2244:
2243:
2241:
2239:
2224:
2218:
2217:
2200:
2194:
2193:
2174:
2168:
2167:
2165:
2163:
2151:
2140:
2139:
2137:
2135:
2095:
2089:
2088:
2086:
2084:
2063:
2055:
2049:
2048:
2046:
2044:
2032:
2026:
2025:
2023:
2021:
2009:
2003:
2002:
2000:
1998:
1986:
1980:
1979:
1977:
1975:
1964:
1958:
1957:
1955:
1953:
1938:
1932:
1931:
1929:
1927:
1916:
1910:
1909:
1907:
1905:
1890:
1884:
1883:
1881:
1879:
1874:. Endpoints News
1868:
1859:
1858:
1856:
1854:
1843:
1837:
1836:
1818:
1792:
1786:
1785:
1757:
1751:
1750:
1740:
1730:
1698:
1689:
1688:
1678:
1668:
1636:
1627:
1626:
1624:
1622:
1617:. March 30, 2022
1615:Retraction Watch
1607:
1601:
1600:
1598:
1596:
1580:
1574:
1573:
1571:
1569:
1554:
1545:
1544:
1542:
1540:
1528:
1519:
1518:
1516:
1514:
1499:
1486:
1485:
1483:
1481:
1470:
1459:
1458:
1452:
1444:
1442:
1440:
1429:
1423:
1422:
1420:
1418:
1407:
1401:
1400:
1398:
1396:
1385:
1379:
1378:
1373:. Archived from
1321:
1298:
1297:
1295:
1293:
1284:. Archived from
1274:
1268:
1267:
1265:
1263:
1246:
1237:
1236:
1234:
1232:
1216:
1205:
1180:
1179:
1177:
1175:
1170:on June 28, 2024
1160:
1154:
1153:
1151:
1149:
1138:
1132:
1131:
1129:
1127:
1116:
1103:
1102:
1100:
1098:
1086:
1075:
1074:
1072:
1070:
1059:
1048:
1047:
1045:
1043:
1020:
975:
974:
972:
970:
955:
949:
948:
946:
944:
929:
918:
917:
907:
883:
870:
869:
867:
865:
851:
845:
844:
842:
840:
825:
819:
818:
816:
814:
791:
740:
739:
737:
735:
720:
703:
696:
690:
683:Barbara Sahakian
675:Jeffrey Cummings
671:
578:Thomas C. SĂĽdhof
491:Labaton Sucharow
487:Jordan A. Thomas
479:citizen petition
448:citizen petition
133:Cassava Sciences
126:
123:
122:.cassavasciences
121:
86:
84:
79:
24:
20:
3209:
3208:
3204:
3203:
3202:
3200:
3199:
3198:
3149:
3148:
3139:Company website
3135:
3130:
3129:
3084:
3080:
3048:
3011:
3007:
2958:(3): e0266629.
2944:
2940:
2891:(3): e0266627.
2877:
2873:
2863:
2861:
2851:
2847:
2812:
2811:
2807:
2789:
2757:Neurobiol Aging
2753:
2749:
2698:
2697:
2693:
2642:
2641:
2637:
2627:
2625:
2616:
2615:
2611:
2601:
2599:
2590:
2589:
2585:
2575:
2573:
2563:
2559:
2549:
2547:
2537:
2533:
2518:
2514:
2504:
2502:
2495:
2491:
2481:
2479:
2469:
2465:
2455:
2453:
2444:
2443:
2439:
2392:
2383:
2373:
2371:
2364:Compliance Week
2356:
2343:
2328:
2326:
2321:
2320:
2316:
2301:
2299:
2282:
2278:
2277:
2273:
2263:
2261:
2251:
2247:
2237:
2235:
2225:
2221:
2201:
2197:
2178:Piller, Charles
2175:
2171:
2161:
2159:
2152:
2143:
2133:
2131:
2099:Piller, Charles
2096:
2092:
2082:
2080:
2061:
2057:
2056:
2052:
2042:
2040:
2033:
2029:
2019:
2017:
2010:
2006:
1996:
1994:
1987:
1983:
1973:
1971:
1966:
1965:
1961:
1951:
1949:
1940:
1939:
1935:
1925:
1923:
1918:
1917:
1913:
1903:
1901:
1892:
1891:
1887:
1877:
1875:
1870:
1869:
1862:
1852:
1850:
1845:
1844:
1840:
1793:
1789:
1758:
1754:
1713:(3): e0266627.
1699:
1692:
1651:(3): e0266629.
1637:
1630:
1620:
1618:
1609:
1608:
1604:
1594:
1592:
1589:Morningstar.com
1581:
1577:
1567:
1565:
1555:
1548:
1538:
1536:
1529:
1522:
1512:
1510:
1500:
1489:
1479:
1477:
1472:
1471:
1462:
1446:
1445:
1438:
1436:
1431:
1430:
1426:
1416:
1414:
1409:
1408:
1404:
1394:
1392:
1387:
1386:
1382:
1325:Piller, Charles
1322:
1301:
1291:
1289:
1288:on June 2, 2022
1276:
1275:
1271:
1261:
1259:
1247:
1240:
1230:
1228:
1206:
1183:
1173:
1171:
1162:
1161:
1157:
1147:
1145:
1140:
1139:
1135:
1125:
1123:
1118:
1117:
1106:
1096:
1094:
1087:
1078:
1068:
1066:
1061:
1060:
1051:
1041:
1039:
1021:
978:
968:
966:
956:
952:
942:
940:
930:
921:
884:
873:
863:
861:
853:
852:
848:
838:
836:
827:
826:
822:
812:
810:
792:
743:
733:
731:
721:
717:
712:
707:
706:
697:
693:
672:
668:
663:
590:
557:
533:neuroscientist
495:Compliance Week
471:
419:
391:
352:
344:opioid receptor
322:
320:FLNA hypothesis
314:
306:
283:
228:
223:
211:
191:
186:
159:clinical trials
135:is an American
118:
82:
80:
77:
67:Pharmaceuticals
49:
17:
12:
11:
5:
3207:
3197:
3196:
3191:
3186:
3181:
3176:
3171:
3166:
3161:
3147:
3146:
3141:
3134:
3133:External links
3131:
3128:
3127:
3098:(4): 1316–38.
3078:
3005:
2938:
2871:
2845:
2805:
2747:
2691:
2635:
2609:
2583:
2557:
2531:
2512:
2489:
2477:Bloomberg News
2463:
2437:
2381:
2341:
2314:
2271:
2245:
2233:New York Times
2219:
2195:
2169:
2141:
2090:
2050:
2027:
2004:
1981:
1959:
1933:
1911:
1885:
1860:
1838:
1787:
1768:(3): 210–220.
1752:
1690:
1628:
1602:
1575:
1546:
1520:
1487:
1460:
1424:
1402:
1380:
1299:
1269:
1238:
1220:The New Yorker
1181:
1155:
1133:
1104:
1076:
1049:
976:
950:
919:
871:
846:
835:. May 10, 2017
820:
741:
729:New York Times
714:
713:
711:
708:
705:
704:
691:
687:Trevor Robbins
665:
664:
662:
659:
589:
586:
574:copy and paste
561:New York Times
556:
553:
535:Matthew Schrag
524:Bloomberg News
502:David S. Bredt
483:whistleblowers
470:
467:
418:
415:
390:
387:
351:
348:
321:
318:
313:
310:
305:
302:
282:
279:
259:Charles Piller
250:The New Yorker
227:
224:
222:
219:
210:
207:
190:
187:
185:
182:
128:
127:
116:
112:
111:
105:
101:
100:
97:
93:
92:
74:
70:
69:
64:
60:
59:
50:
45:
42:
41:
36:
32:
31:
28:
15:
9:
6:
4:
3:
2:
3206:
3195:
3192:
3190:
3187:
3185:
3182:
3180:
3177:
3175:
3172:
3170:
3167:
3165:
3162:
3160:
3157:
3156:
3154:
3145:
3142:
3140:
3137:
3136:
3123:
3119:
3114:
3109:
3105:
3101:
3097:
3093:
3092:J Clin Invest
3089:
3082:
3074:
3073:
3068:
3064:
3060:
3056:
3052:
3045:
3041:
3037:
3033:
3029:
3025:
3022:(1): 247–61.
3021:
3017:
3009:
3001:
2997:
2992:
2987:
2983:
2979:
2974:
2969:
2965:
2961:
2957:
2953:
2949:
2942:
2934:
2930:
2925:
2920:
2916:
2912:
2907:
2902:
2898:
2894:
2890:
2886:
2882:
2875:
2860:
2859:The Scientist
2856:
2849:
2841:
2837:
2832:
2827:
2824:: 152. 2022.
2823:
2819:
2815:
2809:
2801:
2797:
2793:
2786:
2782:
2778:
2774:
2770:
2766:
2762:
2758:
2751:
2743:
2739:
2734:
2729:
2725:
2721:
2717:
2713:
2709:
2705:
2701:
2695:
2687:
2683:
2678:
2673:
2669:
2665:
2661:
2657:
2653:
2649:
2645:
2639:
2623:
2619:
2613:
2597:
2593:
2587:
2572:
2568:
2561:
2546:
2542:
2535:
2527:
2523:
2516:
2500:
2493:
2478:
2474:
2467:
2451:
2447:
2441:
2433:
2429:
2425:
2421:
2417:
2413:
2409:
2405:
2401:
2397:
2390:
2388:
2386:
2369:
2365:
2361:
2354:
2352:
2350:
2348:
2346:
2338:
2324:
2318:
2311:
2298:
2294:
2290:
2289:
2281:
2275:
2260:
2256:
2249:
2234:
2230:
2223:
2215:
2211:
2207:
2199:
2191:
2187:
2183:
2179:
2173:
2157:
2150:
2148:
2146:
2130:
2126:
2122:
2118:
2114:
2110:
2109:
2104:
2100:
2094:
2079:
2075:
2071:
2067:
2060:
2054:
2038:
2031:
2015:
2008:
1992:
1985:
1969:
1963:
1947:
1943:
1937:
1921:
1915:
1899:
1895:
1889:
1873:
1867:
1865:
1848:
1842:
1834:
1830:
1826:
1822:
1817:
1812:
1808:
1804:
1803:
1798:
1791:
1783:
1779:
1775:
1771:
1767:
1763:
1756:
1748:
1744:
1739:
1734:
1729:
1724:
1720:
1716:
1712:
1708:
1704:
1697:
1695:
1686:
1682:
1677:
1672:
1667:
1662:
1658:
1654:
1650:
1646:
1642:
1635:
1633:
1616:
1612:
1606:
1590:
1586:
1579:
1564:
1560:
1553:
1551:
1534:
1527:
1525:
1509:
1505:
1498:
1496:
1494:
1492:
1475:
1469:
1467:
1465:
1456:
1450:
1434:
1428:
1412:
1406:
1390:
1384:
1376:
1372:
1368:
1364:
1360:
1356:
1352:
1348:
1344:
1340:
1336:
1335:
1330:
1326:
1320:
1318:
1316:
1314:
1312:
1310:
1308:
1306:
1304:
1287:
1283:
1279:
1273:
1258:
1257:
1252:
1245:
1243:
1226:
1222:
1221:
1215:
1210:
1204:
1202:
1200:
1198:
1196:
1194:
1192:
1190:
1188:
1186:
1169:
1165:
1159:
1143:
1137:
1121:
1115:
1113:
1111:
1109:
1092:
1085:
1083:
1081:
1064:
1058:
1056:
1054:
1038:
1034:
1030:
1026:
1019:
1017:
1015:
1013:
1011:
1009:
1007:
1005:
1003:
1001:
999:
997:
995:
993:
991:
989:
987:
985:
983:
981:
965:
961:
954:
939:
935:
928:
926:
924:
915:
911:
906:
901:
897:
893:
889:
882:
880:
878:
876:
860:
856:
850:
834:
830:
824:
809:
805:
801:
797:
790:
788:
786:
784:
782:
780:
778:
776:
774:
772:
770:
768:
766:
764:
762:
760:
758:
756:
754:
752:
750:
748:
746:
730:
726:
719:
715:
701:
695:
688:
684:
680:
679:Steven Arnold
676:
670:
666:
658:
656:
652:
651:
645:
642:
641:
635:
633:
629:
628:
623:
621:
617:
614:
613:
607:
605:
602:it issued an
600:
599:
593:
585:
583:
579:
575:
571:
570:Elisabeth Bik
567:
562:
552:
548:
544:
541:
536:
532:
527:
525:
520:
515:
511:
507:
503:
498:
496:
492:
488:
484:
480:
476:
466:
462:
459:
455:
453:
449:
445:
441:
439:
435:
430:
428:
424:
414:
412:
407:
403:
398:
397:
386:
384:
378:
376:
372:
367:
365:
361:
357:
347:
345:
341:
337:
336:
331:
327:
317:
309:
301:
299:
293:
291:
286:
278:
276:
275:
270:
266:
265:
261:, writing in
260:
257:According to
255:
252:
251:
246:
245:Patrick Keefe
242:
240:
239:Lindsay Burns
236:
232:
218:
216:
206:
204:
200:
196:
181:
179:
174:
172:
171:Lindsay Burns
168:
164:
160:
157:
153:
149:
144:
142:
141:Austin, Texas
138:
134:
125:
117:
113:
109:
108:Austin, Texas
106:
102:
98:
94:
90:
75:
71:
68:
65:
61:
58:
54:
51:
48:
43:
40:
37:
33:
29:
25:
19:
3095:
3091:
3081:
3071:
3069:,
3019:
3016:Neuroscience
3015:
3008:
2955:
2951:
2941:
2888:
2884:
2874:
2862:. Retrieved
2858:
2848:
2821:
2817:
2808:
2760:
2756:
2750:
2707:
2703:
2694:
2651:
2647:
2638:
2626:. Retrieved
2612:
2600:. Retrieved
2586:
2574:. Retrieved
2570:
2560:
2548:. Retrieved
2544:
2534:
2525:
2515:
2503:. Retrieved
2492:
2480:. Retrieved
2466:
2456:September 4,
2454:. Retrieved
2449:
2440:
2399:
2395:
2374:September 2,
2372:. Retrieved
2368:the original
2327:. Retrieved
2317:
2300:. Retrieved
2286:
2274:
2262:. Retrieved
2258:
2248:
2236:. Retrieved
2232:
2222:
2205:
2198:
2172:
2160:. Retrieved
2132:. Retrieved
2112:
2106:
2093:
2081:. Retrieved
2065:
2053:
2041:. Retrieved
2030:
2018:. Retrieved
2007:
1995:. Retrieved
1984:
1972:. Retrieved
1962:
1950:. Retrieved
1945:
1936:
1924:. Retrieved
1914:
1902:. Retrieved
1897:
1888:
1876:. Retrieved
1851:. Retrieved
1841:
1806:
1800:
1790:
1765:
1761:
1755:
1710:
1706:
1648:
1644:
1621:September 1,
1619:. Retrieved
1605:
1593:. Retrieved
1588:
1578:
1566:. Retrieved
1562:
1537:. Retrieved
1511:. Retrieved
1507:
1478:. Retrieved
1437:. Retrieved
1427:
1415:. Retrieved
1405:
1393:. Retrieved
1383:
1375:the original
1338:
1332:
1290:. Retrieved
1286:the original
1281:
1272:
1260:. Retrieved
1254:
1229:. Retrieved
1218:
1172:. Retrieved
1168:the original
1164:"Management"
1158:
1146:. Retrieved
1136:
1124:. Retrieved
1095:. Retrieved
1067:. Retrieved
1063:"Management"
1040:. Retrieved
1028:
969:September 2,
967:. Retrieved
953:
941:. Retrieved
895:
891:
862:. Retrieved
859:CNN Business
858:
849:
837:. Retrieved
832:
823:
811:. Retrieved
799:
732:. Retrieved
728:
718:
694:
669:
648:
646:
640:Neuroscience
638:
636:
625:
624:
619:
618:
610:
609:The journal
608:
596:
594:
591:
560:
558:
549:
545:
528:
514:Western blot
509:
499:
472:
463:
457:
456:
442:
437:
431:
420:
394:
392:
382:
379:
368:
353:
346:signaling.)
333:
323:
315:
307:
294:
287:
284:
272:
262:
256:
248:
243:
237:
233:
229:
212:
192:
175:
145:
132:
131:
104:Headquarters
99:Remi Barbier
35:Company type
18:
3053:, see
2794:, see
2337:Piller 2022
2310:Piller 2022
2264:October 29,
2238:October 17,
1591:. Dow Jones
1535:. Stat News
1148:October 23,
1093:. STAT news
1069:October 23,
324:Filamin A (
209:Name change
3153:Categories
2763:: 99–114.
2628:August 20,
2602:August 20,
2545:Reason.com
2482:August 20,
2329:August 19,
2302:August 19,
2214:2876611078
1993:. NBC News
1926:August 31,
1809:(8): 934.
710:References
298:meme stock
226:Leadership
2982:1932-6203
2915:1932-6203
2864:April 28,
2840:247586479
2785:207163555
2724:0270-6474
2668:0270-6474
2576:August 6,
2550:March 31,
2526:Bloomberg
2505:April 29,
2432:255801597
2158:. Reuters
2039:. Reuters
2016:. Reuters
1952:April 30,
1853:April 29,
1371:250953611
1262:April 30,
1231:April 29,
1042:April 28,
1037:0362-4331
943:April 29,
813:April 29,
808:0099-9660
632:retracted
396:simufilam
371:oxycodone
281:Financial
247:wrote in
156:phase III
148:simufilam
139:based in
47:Traded as
3122:22476197
3067:35031084
3044:42012168
3036:16084657
3000:35353864
2952:PLOS ONE
2933:35353861
2885:PLOS ONE
2777:28438486
2742:34921050
2686:34759033
2424:36639445
2398:(News).
2210:ProQuest
2162:July 31,
2134:July 10,
2129:38484070
2083:July 10,
2072:. 2024.
2020:June 29,
1997:June 29,
1974:June 29,
1878:June 15,
1833:20266178
1825:16082357
1782:20726836
1747:35353861
1707:PLOS ONE
1685:35353864
1645:PLOS ONE
1595:June 29,
1568:June 29,
1539:June 29,
1513:June 29,
1480:June 29,
1449:cite web
1439:July 31,
1417:July 31,
1395:July 31,
1363:35862524
1225:Archived
1174:July 18,
1126:July 18,
1097:July 18,
914:16242645
734:July 19,
627:PLOS One
304:Staffing
189:Founding
63:Industry
27:Formerly
3113:3314463
2991:8967007
2960:Bibcode
2924:8967022
2893:Bibcode
2733:8802929
2677:8672690
2571:Reuters
2404:Bibcode
2288:Science
2108:Science
2070:Science
2043:July 2,
1738:8967022
1715:Bibcode
1676:8967007
1653:Bibcode
1343:Bibcode
1334:Science
964:Reuters
655:insulin
637:A 2005
519:shorted
444:Reuters
438:Science
330:amyloid
264:Science
195:opioids
184:History
115:Website
96:Founder
81: (
73:Founded
55::
3120:
3110:
3065:
3061:,
3042:
3034:
2998:
2988:
2980:
2931:
2921:
2913:
2838:
2783:
2775:
2740:
2730:
2722:
2684:
2674:
2666:
2430:
2422:
2396:Nature
2212:
2127:
1904:May 3,
1831:
1823:
1780:
1745:
1735:
1683:
1673:
1369:
1361:
1292:May 2,
1035:
912:
864:May 7,
839:May 7,
806:
356:opioid
110:, U.S.
91:, U.S.
53:Nasdaq
39:Public
3040:S2CID
2836:S2CID
2781:S2CID
2428:S2CID
2283:(PDF)
2062:(PDF)
1829:S2CID
1367:S2CID
661:Notes
3118:PMID
3063:PMID
3032:PMID
2996:PMID
2978:ISSN
2929:PMID
2911:ISSN
2866:2022
2773:PMID
2738:PMID
2720:ISSN
2682:PMID
2664:ISSN
2630:2022
2604:2022
2578:2024
2552:2024
2507:2022
2484:2022
2458:2022
2420:PMID
2376:2022
2331:2022
2308:See
2304:2022
2266:2023
2240:2023
2164:2022
2136:2024
2125:PMID
2085:2024
2045:2024
2022:2014
1999:2014
1976:2024
1954:2022
1928:2022
1906:2022
1880:2022
1855:2022
1821:PMID
1778:PMID
1743:PMID
1681:PMID
1623:2022
1597:2024
1570:2024
1541:2024
1515:2024
1482:2024
1455:link
1441:2022
1419:2022
1397:2022
1359:PMID
1294:2022
1264:2022
1256:Stat
1233:2022
1176:2024
1150:2023
1128:2024
1099:2024
1071:2023
1044:2022
1033:ISSN
971:2022
945:2022
910:PMID
866:2022
841:2022
815:2022
804:ISSN
736:2024
698:See
411:Stat
362:for
326:FLNA
124:.com
83:1998
76:1998
57:SAVA
3108:PMC
3100:doi
3096:122
3055:doi
3024:doi
3020:135
2986:PMC
2968:doi
2919:PMC
2901:doi
2826:doi
2822:113
2796:doi
2765:doi
2728:PMC
2712:doi
2672:PMC
2656:doi
2412:doi
2400:613
2293:doi
2186:doi
2117:doi
2113:383
2074:doi
2066:FDA
1811:doi
1770:doi
1733:PMC
1723:doi
1671:PMC
1661:doi
1351:doi
1339:377
900:doi
366:).
120:www
87:in
3155::
3116:.
3106:.
3094:.
3090:.
3038:.
3030:.
3018:.
2994:.
2984:.
2976:.
2966:.
2956:17
2954:.
2950:.
2927:.
2917:.
2909:.
2899:.
2889:17
2887:.
2883:.
2857:.
2834:.
2820:.
2816:.
2779:.
2771:.
2761:55
2759:.
2736:.
2726:.
2718:.
2708:42
2706:.
2702:.
2680:.
2670:.
2662:.
2652:41
2650:.
2646:.
2620:.
2594:.
2569:.
2543:.
2524:.
2475:.
2448:.
2426:.
2418:.
2410:.
2384:^
2362:.
2344:^
2285:.
2257:.
2231:.
2208:.
2144:^
2123:.
2111:.
2105:.
2068:.
2064:.
1944:.
1896:.
1863:^
1827:.
1819:.
1807:23
1805:.
1799:.
1776:.
1764:.
1741:.
1731:.
1721:.
1711:17
1709:.
1705:.
1693:^
1679:.
1669:.
1659:.
1649:17
1647:.
1643:.
1631:^
1613:.
1587:.
1561:.
1549:^
1523:^
1506:.
1490:^
1463:^
1451:}}
1447:{{
1365:.
1357:.
1349:.
1337:.
1331:.
1302:^
1280:.
1253:.
1241:^
1223:.
1217:.
1184:^
1107:^
1079:^
1052:^
1031:.
1027:.
979:^
962:.
936:.
922:^
908:.
896:12
894:.
890:.
874:^
857:.
831:.
802:.
798:.
744:^
727:.
685:,
681:,
677:,
559:A
3124:.
3102::
3075:)
3057::
3046:.
3026::
3002:.
2970::
2962::
2935:.
2903::
2895::
2868:.
2842:.
2828::
2802:)
2798::
2787:.
2767::
2744:.
2714::
2688:.
2658::
2632:.
2606:.
2580:.
2554:.
2528:.
2509:.
2486:.
2460:.
2434:.
2414::
2406::
2378:.
2339:.
2333:.
2312:.
2306:.
2295::
2268:.
2242:.
2216:.
2192:.
2188::
2166:.
2138:.
2119::
2087:.
2076::
2047:.
2024:.
2001:.
1978:.
1956:.
1930:.
1908:.
1882:.
1857:.
1835:.
1813::
1784:.
1772::
1766:5
1749:.
1725::
1717::
1687:.
1663::
1655::
1625:.
1599:.
1572:.
1543:.
1517:.
1484:.
1457:)
1443:.
1421:.
1399:.
1353::
1345::
1296:.
1266:.
1235:.
1178:.
1152:.
1130:.
1101:.
1073:.
1046:.
973:.
947:.
916:.
902::
868:.
843:.
817:.
738:.
85:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.